R&D 5 changes underway for R&D IT shifting to advanced modalitie... Back in 2000, the FDA approved only six biologics versus 27 new molecular entities (NMEs).
News Boehringer raises hope of oral drug for diabetic eye disease Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face